Tumor-derived exosomes carrying PD-L1 provide critical insights for developing novel checkpoint inhibitor therapies [141], while dendritic cell-derived exosomes presenting tumor antigens have been shown to enhance T-cell activation and improve immune responses in melanoma and NSCLC patients [253]. Here, CD274 is linked to neoplasm.